Investigational Drug Information for UGN-102
What is the drug development status for UGN-102?
UGN-102 is an investigational drug.
There have been 5 clinical trials for UGN-102.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 29th 2024.
The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, and Carcinoma. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].
There are zero US patents protecting this investigational drug and zero international patents.
Summary for UGN-102
| US Patents | 1,310 |
| International Patents | 10,431 |
| US Patent Applications | 4,767 |
| WIPO Patent Applications | 2,661 |
| Japanese Patent Applications | 610 |
| Clinical Trial Progress | Phase 2 (2024-08-29) |
| Vendors | 48 |
Recent Clinical Trials for UGN-102
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | UroGen Pharma Ltd. | PHASE3 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | UroGen Pharma Ltd. | Phase 3 |
Clinical Trial Summary for UGN-102
Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102
US Patents for UGN-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| UGN-102 | ⤷ Start Trial | Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same | Immunogen Inc | ⤷ Start Trial |
| UGN-102 | ⤷ Start Trial | Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same | Samsung Life Public Welfare Foundation | ⤷ Start Trial |
| UGN-102 | ⤷ Start Trial | Bio-orthogonal drug activation | Tagworks Pharmaceuticals BV | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for UGN-102
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| UGN-102 | Australia | AU2003285878 | 2022-11-07 | ⤷ Start Trial |
| UGN-102 | Brazil | BR0316101 | 2022-11-07 | ⤷ Start Trial |
| UGN-102 | Canada | CA2504818 | 2022-11-07 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
